Abbott introduced a new delivery system for its Proclaim DRG neurostimulation technology, which aims to streamline implantation procedures for electrodes targeting the dorsal root ganglion (DRG). This new system offers enhanced maneuverability, allowing physicians to access the precise placement area, crucial for treating complex regional pain syndrome (CRPS) Types 1 and 2.
Abbott's Proclaim DRG system is currently the sole FDA-approved technology for treating CRPS in the lower extremities. The DRG, a cluster of nerve cells along the spine, controls pain signals from areas like the pelvis, hip, and knee. Abbott developed its DRG therapy to disrupt pain signals, offering relief to sufferers of CRPS, a condition more painful than childbirth or amputation.
The neuromodulation system comprises an implantable pulse generator producing electrical stimulation and leads delivering it to targeted DRG areas. According to Abbott, four out of five users have reported significant pain relief, with an average drop of 81% in pain intensity.
Timothy Deer, M.D., president of the Spine and Nerve Centers of the Virginias, noted the improved design enhances maneuverability, potentially enabling more physicians to perform the procedure. Allen Burton, M.D., Abbott's medical director of neuromodulation, emphasized the importance of continual improvement in DRG technology to enhance patient outcomes and improve quality of life.
CRPS is classified into Type 1, occurring without detectable nerve damage, and Type 2, which follows known nerve damage. While some experience mild symptoms, others suffer severe, long-term pain and disability.
Abbott, a leader in healthcare with operations across diagnostics, medical devices, and nutrition, continues to innovate in pain management breakthroughs. Further safety information on the Proclaim DRG system is available on their website.